José Perea García, General and Digestive Surgeon affiliated with Humanitas Research Hospital in Milan and Vithas Arturo Soria University Hospital in Madrid, shared on LinkedIn:
“Is early-onset colorectal cancer immunologically different from colorectal cancer diagnosed later in life?
Happy to share our new review published in Cancer Immunology Research, AACR Journals:
“Tumor-Immune Microenvironment of Early-Onset Colorectal Cancer: Implications for Immune-Based Prevention and Therapy.”
We explore how the tumor-immune microenvironment (TiME) may contribute to the development, progression, prevention, and treatment of early-onset colorectal cancer (EOCRC).
Key messages:
- EOCRC is not simply colorectal cancer occurring earlier in life: Its biology reflects complex interactions among host susceptibility, immune regulation, molecular alterations, and environmental exposures.
- The immune microenvironment is not necessarily more or less inflamed in younger patients — it may be differently organized:Functional immune states, spatial distribution, antigen presentation, and tumor–immune communication may be more informative than immune-cell abundance alone.
- The microbiome–immune axis may be particularly relevant in EOCRC:Early-life exposures, microbial dysbiosis, and genotoxic bacteria, including colibactin-producing E. coli, may influence carcinogenesis and immune evolution.
- Immunogenomic and epigenomic alterations shape immune recognition and escape:Mismatch repair status, mutational signatures, chromosomal instability, and DNA methylation contribute to heterogeneous immune phenotypes.
- Microsatellite-stable (MSS) EOCRC represents a major therapeutic challenge:Understanding its immune heterogeneity could help identify new biomarkers and rational immunotherapy combinations.
- Prevention and treatment should be connected through host–tumor biology:Integrating host susceptibility, environmental exposures, microbiome, and immune profiling may open opportunities for risk-adapted screening, immune-based prevention, and personalized treatment.
Our central message: Age at colorectal cancer diagnosis should not be considered merely a demographic variable, but a potentially meaningful biological dimension in tumor–host interactions.
The next challenge is to translate these insights into prospective, integrated multiomic studies and clinically actionable strategies.
Grateful to the coauthors for this collaboration!”
Title: Tumor-Immune Microenvironment of Early-Onset Colorectal Cancer: Implications for Immune-Based Prevention and Therapy
Authors: María González-Sanmartín, Mayte Coiras, Shuji Ogino
Read the Full Article.
You can also read:
Other articles about Colorectal Cancer on OncoDaily.
